Deep Brain Stimulation (DBS) is a novel surgical technique
involving the direct implantation of microscopic electrodes to
preselected specific neuroanatomical structures, which generate
an electrical impulse to modulate the activity of those neural
networks that have been associated with MDD symptoms
(Qurran et al., 2013). Although some open-label studies have been
successful, approximately 50% of patients who undergo DBS do
not in fact achieve any significant benefit.
An open-label trial investigating the effectiveness of Vagal
Nerve Stimulation (VNS) augmentation with pharmacological
treatment in treatment-resistant MDD individuals demonstrated
that following 10 weeks of regular treatment, the response
and remission rates were found to be 40% and 17% respectively
(Rush et al., 2000). However, the results of VNS often requires a
long duration and number of treatments, therefore it will likely
not be recommended for individuals with acute TRD (Cousin
and Dougherty, 2012). Although there are some positive results
regarding the efficacy of each of these novel somatic therapies
the area remains largely experimental and further research,
specifically in TRD populations, will be necessary before any
recommendations can be given.
Deep Brain Stimulation (DBS) is a novel surgical techniqueinvolving the direct implantation of microscopic electrodes topreselected specific neuroanatomical structures, which generatean electrical impulse to modulate the activity of those neuralnetworks that have been associated with MDD symptoms(Qurran et al., 2013). Although some open-label studies have beensuccessful, approximately 50% of patients who undergo DBS donot in fact achieve any significant benefit.An open-label trial investigating the effectiveness of VagalNerve Stimulation (VNS) augmentation with pharmacologicaltreatment in treatment-resistant MDD individuals demonstratedthat following 10 weeks of regular treatment, the responseand remission rates were found to be 40% and 17% respectively(Rush et al., 2000). However, the results of VNS often requires along duration and number of treatments, therefore it will likelynot be recommended for individuals with acute TRD (Cousinand Dougherty, 2012). Although there are some positive resultsregarding the efficacy of each of these novel somatic therapiesthe area remains largely experimental and further research,specifically in TRD populations, will be necessary before anyrecommendations can be given.
การแปล กรุณารอสักครู่..